MedPath

Randomized trial of micronutrient-fortified salt in women in Southern India

Phase 3
Registration Number
CTRI/2024/04/066208
Lead Sponsor
Cornell University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Women between 18 and 49 years of age

- Healthy

- Not pregnant or lactating

- Plan to reside in the catchment area of our periconceptional surveillance program for at least two years

Exclusion Criteria

- Severe anemia, i.e., Hemoglobin less than 8.0 g/dL

- Reported diagnosis of HIV, malaria infection, or active tuberculosis disease

- Malabsorption disorders

- Stage 2 hypertension, i.e., SBP =140 or DBP =90 mmHg

- Glycated hemoglobin, HbA1c =6.5%

- Other serious pre-existing medical conditions, active infections, or acute illnesses

- Previous pregnancy affected by a neural tube defect

- Planning to become pregnant in the next 12 months

- Daily micronutrient supplements, i.e., tablets capsules or dispersible tablets =4 times in the past week

- Intramuscular or intravenous interventions containing medications or micronutrients in the past 3 months

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
- Red blood cell (RBC) folate and serum folate concentrations, nmol/L <br/ ><br>- Hemoglobin concentrations, g/dL <br/ ><br>- Vitamin B12 concentrations, pmol/LTimepoint: Endpoint, i.e., 12 months
Secondary Outcome Measures
NameTimeMethod
Anemia, i.e., Hemoglobin less than 12.0 g/dLTimepoint: Endpoint, i.e., 12 months;Folate deficiency and insufficiency, i.e., RBC folate less than 305 nmol/L and less than 748 nmol/LTimepoint: Endpoint, i.e., 12 months;Vitamin B12 deficiency and insufficiency i.e., total vitamin B12 less than 148.0 pmol/L and less than 221.0 pmol/LTimepoint: Endpoint, i.e., 12 months
© Copyright 2025. All Rights Reserved by MedPath